Tuberculosis bacteria are changing how they trigger immunity

Tuberculosis remains a major global health threat because the bacterium Mycobacterium tuberculosis (Mtb) can vary widely in how it causes disease and spreads. That variation — in virulence, transmissibility, and the kinds of disease people get — arises in part from differences among bacterial strains that have co-evolved with humans for thousands of years. To dig into which bacterial features drive those differences, a research team led by corresponding author Sarah M. Fortune developed new tools and carried out a large survey of clinical bacteria. Their work focused on bacterial gene activity, not just DNA sequences, because the level at which genes are turned on or off can affect how the bacteria behave inside people. Using new RNA-seq and phylogenomic approaches, they captured the active transcriptomes of hundreds of Mtb isolates and then linked that transcriptional variation to genetic differences and to patterns seen in epidemiologic data. The study set out to move beyond cataloguing mutations to understanding how changes in gene expression might shape transmission, disease, and the bacterial response to drugs.

The team combined RNA-seq and phylogenomic tools to measure gene expression across a large set of clinical samples and to place those expression patterns in a genetic and epidemiologic context. Across 274 Mtb clinical isolates they observed unexpected diversity in the expression of virulence genes and were able to connect that diversity to both known regulators and regulators not previously recognized. A striking finding was that many isolates harbor genetic variants associated with decreased expression of EsxA (Esat6) and EsxB (Cfp10). The abstract emphasizes that EsxA (Esat6) and EsxB (Cfp10) are virulence effectors, dominant T cell antigens, and immunodiagnostic targets, meaning changes in their expression could alter immune recognition and diagnostic signals. Looking beyond the initial set, the researchers examined patterns across more than 55,000 isolates and found these expression-linked variants are associated with increased transmissibility, a relationship that was especially strong in drug resistant Mtb strains. In short, the work linked transcriptional changes to genetic variants and to real-world patterns of spread, highlighting a possible evolutionary trajectory under drug pressure.

The findings suggest that expression of key Mtb virulence genes is evolving among circulating bacteria in ways that may help the pathogen survive and spread, particularly when antibiotics exert pressure on populations. If variants that lower expression of major antigens such as EsxA (Esat6) and EsxB (Cfp10) become more common, there are two immediate concerns. First, immunodiagnostic tests that rely on these proteins could become less reliable if the bacteria stop producing them at the levels expected by current assays. Second, vaccines in development that target these antigens might lose effectiveness if antigen expression shifts in the circulating strains. The authors describe this as a sobering implication: bacterial evolution in response to drug pressure could reshape the targets used for diagnosis and prevention, and public health strategies will need to account for changing patterns of antigen expression as well as genetic resistance markers.